Elisabeth I Heath

Elisabeth I Heath

UNVERIFIED PROFILE

Are you Elisabeth I Heath?   Register this Author

Register author
Elisabeth I Heath

Elisabeth I Heath

Publications by authors named "Elisabeth I Heath"

Are you Elisabeth I Heath?   Register this Author

76Publications

1673Reads

7Profile Views

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

CA Cancer J Clin 2019 Jul 22;69(4):305-343. Epub 2019 May 22.

Professor of Medicine and Oncology, Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Institute, MedStar Georgetown Cancer Institute, Washington, DC.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21560
Publisher Site
http://dx.doi.org/10.3322/caac.21560DOI Listing
July 2019

Prostate Cancer National Summit's Call to Action.

Clin Genitourin Cancer 2019 Jun 16;17(3):161-168. Epub 2019 Apr 16.

Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.04.002DOI Listing
June 2019

Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Cancer Metastasis Rev 2018 12;37(4):655-663

Department of Oncology, Wayne State University School of Medicine, Detroit, MI, 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-018-9767-4DOI Listing
December 2018

Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.

Anticancer Res 2018 Nov;38(11):6361-6366

Department of Pathology, Wayne State University School of Medicine, Detroit, MI, U.S.A.

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.12
Publisher Site
http://dx.doi.org/10.21873/anticanres.12994DOI Listing
November 2018

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Cell 2018 06;173(7):1770-1782.e14

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.04.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084431PMC
June 2018

Racial Disparities in the Molecular Landscape of Cancer.

Anticancer Res 2018 04;38(4):2235-2240

West Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Tennessee, Memphis, TN, U.S.A.

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/content/38/4/2235.abstract
Publisher Site
http://dx.doi.org/10.21873/anticanres.12466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123828PMC
April 2018

Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.

Clin Genitourin Cancer 2017 08 27;15(4):463-471. Epub 2016 Oct 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.10.006DOI Listing
August 2017

Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.

Mol Cancer 2016 11 3;15(1):68. Epub 2016 Nov 3.

Department of Urology, Wayne State University, School of Medicine, 9245 Scott Hall, 540 E. Canfield Avenue, Detroit, MI, 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-016-0552-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093938PMC
November 2016

Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.

Clin Genitourin Cancer 2016 10 10;14(5):373-380.e2. Epub 2016 Mar 10.

Department of Hematology-Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.03.002DOI Listing
October 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

New developments in prostate cancer therapy.

Am Soc Clin Oncol Educ Book 2012 :309-13

From the Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.309DOI Listing
April 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

Invest New Drugs 2016 Apr 29;34(2):225-30. Epub 2016 Feb 29.

University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0334-yDOI Listing
April 2016

Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

Am J Transl Res 2016 15;8(1):166-76. Epub 2016 Jan 15.

Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759426PMC
April 2016

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Mar 20;77(3):527-38. Epub 2016 Jan 20.

Wisconsin Institute for Medical Research, University of Wisconsin Carbone Cancer Center, Room 7105, 1111 Highland Avenue, Madison, WI, 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2958-1DOI Listing
March 2016

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol 2015 May 6;33(14):1601-8. Epub 2015 Apr 6.

Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417730PMC
May 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Promising areas of prostate cancer research.

Cancer Metastasis Rev 2014 Sep;33(2-3):375-6

Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, HW04H0, Detroit, MI, 48201, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9491-zDOI Listing
September 2014

Reply to G. Procopio et al.

J Clin Oncol 2014 Sep 28;32(27):3083-4. Epub 2014 Jul 28.

Karmanos Cancer Institute; Wayne State University School of Medicine, Detroit, MI

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.8501DOI Listing
September 2014

The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma.

J Clin Oncol 2014 Mar 10;32(8):729-34. Epub 2014 Feb 10.

Henry Ford Health Systems, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.6029DOI Listing
March 2014

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2013 Apr 13;71(4):883-92. Epub 2013 Jan 13.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2079-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609871PMC
April 2013

Physicians' Use of Patients' Daily Reports of Quality of Life to Evaluate Treatment Response in Phase I Cancer Trials.

J Cancer Ther 2012 Oct;3(5):582-588

Karmanos Cancer Institute Communication and Behavioral Oncology Program, Detroit, USA ; Wayne State University School of Medicine Department of Oncology, Wayne, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jct.2012.35074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777632PMC
October 2012

Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.

Prostate Cancer 2012 28;2012:640968. Epub 2012 Aug 28.

Department of Urology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/640968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434411PMC
September 2012

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.

Invest New Drugs 2012 Aug 3;30(4):1566-74. Epub 2011 Aug 3.

Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-011-9725-2DOI Listing
August 2012

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.

Expert Opin Biol Ther 2011 Nov 31;11(11):1519-24. Epub 2011 Aug 31.

Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2011.610788DOI Listing
November 2011

Apocrine carcinoma of the face in a 62-year-old Asian man.

Clin Pract 2011 Jul 1;1(3):e50. Epub 2011 Jul 1.

Department of Internal Medicine, Division of Hematology/Oncology, Wayne State University, Karmanos Cancer Insitute, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/cp.2011.e50DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981381PMC
July 2011

Angiogenesis inhibitors in the treatment of prostate cancer.

J Hematol Oncol 2010 Aug 2;3:26. Epub 2010 Aug 2.

Department of Internal Medicine, Henry Ford Hospital, CFP 559, 2799 West Grand Blvd, Detroit, MI 48202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-3-26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922886PMC
August 2010

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Clin Cancer Res 2010 Jul 14;16(13):3507-16. Epub 2010 May 14.

Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0574DOI Listing
July 2010

Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial.

Dis Esophagus 2008 2;21(7):641-4. Epub 2008 Jun 2.

The Robert Wood Johnson Foundation, Princeton, New Jersey 08543-2316, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1442-2050.2008.00835.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612967PMC
March 2009

Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report.

Urol Oncol 2008 Jan-Feb;26(1):53-5. Epub 2007 Nov 7.

Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2006.12.017DOI Listing
February 2008

New targets in the management of prostate cancer.

Hematol Oncol Clin North Am 2006 Aug;20(4):985-99, xi

Barbara Ann Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2006.05.001DOI Listing
August 2006

Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy.

Ann Thorac Surg 2002 Jul;74(1):227-31; discussion 231

Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0003-4975(02)03655-xDOI Listing
July 2002

Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.

Invest New Drugs 2002 Feb;20(1):95-9

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
February 2002